Trovan is a drug owned by Pfizer Central Research. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 20, 2019. Details of Trovan's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6187341 | Trovafloxacin mesylate tablet |
Jan, 2019
(5 years ago) |
Expired
|
| US5763454 | Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt |
Jun, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Trovan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Trovan's family patents as well as insights into ongoing legal events on those patents.
Trovan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Trovan's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 20, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Trovan Generics:
There are no approved generic versions for Trovan as of now.
Alternative Brands for Trovan
Trovan which is used for treating bacterial infections., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Baxter Hlthcare Corp |
| |||||
| Cubist Pharms Llc |
| |||||
| Cumberland |
| |||||
| Lg Chem Ltd |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Rempex |
| |||||
| Shionogi Inc |
| |||||
| Wyeth Pharms |
| |||||
| Xellia Pharms Aps |
| |||||
About Trovan
Trovan is a drug owned by Pfizer Central Research. It is used for treating bacterial infections. Trovan uses Trovafloxacin Mesylate as an active ingredient. Trovan was launched by Pfizer in 1997.
Approval Date:
Trovan was approved by FDA for market use on 18 December, 1997.
Active Ingredient:
Trovan uses Trovafloxacin Mesylate as the active ingredient. Check out other Drugs and Companies using Trovafloxacin Mesylate ingredient
Treatment:
Trovan is used for treating bacterial infections.
Dosage:
Trovan is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 200MG BASE | TABLET | Discontinued | ORAL |
| EQ 100MG BASE | TABLET | Discontinued | ORAL |